On 9 February 2021, the China National IP Administration (CNIPA)
published draft Administrative Adjudication Measures for Early
Resolution Mechanism for Drug Patent Disputes
(https://www.cnipa.gov.cn/art/2021/2/9/art_75_156702.html,
hereinafter drug patent linkage measures) for comments by 27 March
2021.
In less than one month, on 2 March 2021, CNIPA published draft
Measures for Administrative Adjudication of Major Patent
Infringement Disputes
(https://www.cnipa.gov.cn/art/2021/3/2/art_75_157045.html,
hereinafter major case measures) for comments by 2 April 2021.
These drafts relate to the 4th Amendment to China's Patent
Law that will come into force on June 1, 2021, which empowers the
CNIPA to adjudicate drug patent disputes, and major patent
infringement disputes, respectively (see my article
https://www.linkedin.com/pulse/4th-amendments-chinese-patent-law-toby-mak/?lipi=urn%3
